Revefenacin's Bioavailability and Absorption
Revefenacin, an anticholinergic bronchodilator, demonstrates variable oral bioavailability. Following oral administration, the maximum plasma concentration (Cmax) of revefenacin is typically reached within 2 to 4 hours [1]. The absolute bioavailability of revefenacin following oral dosing is approximately 36% [1]. This indicates that a significant portion of the administered dose does not enter systemic circulation.
How is Revefenacin Absorbed in the Body?
Once ingested, revefenacin is absorbed from the gastrointestinal tract. The absorption process leads to peak plasma levels within a few hours. While its absolute bioavailability is around 36%, the drug is still effective for treating respiratory conditions.
What are Revefenacin's Drug Interactions?
Revefenacin's bioavailability can be influenced by other medications. It is a substrate of the cytochrome P450 enzyme CYP3A4 [1]. This means that drugs that inhibit or induce CYP3A4 could potentially alter revefenacin plasma concentrations. For example, co-administration with strong CYP3A4 inhibitors might increase revefenacin exposure, while strong CYP3A4 inducers could decrease it [1].
How is Revefenacin Metabolized and Excreted?
Revefenacin undergoes extensive hepatic metabolism, primarily via CYP3A4 [1]. The drug is eliminated from the body through both renal and hepatic routes. After oral administration of a radiolabeled dose, approximately 58% of the radioactivity was recovered in the urine and 31% in the feces within 10 days [1]. This suggests a substantial contribution of both kidney and liver to the drug's clearance. The mean half-life of revefenacin in plasma is approximately 5 to 6 hours [1].
What is the Recommended Dosage for Revefenacin?
The recommended dosage for revefenacin is typically 175 mcg administered orally twice daily [2]. Dosing adjustments may be necessary for patients with specific conditions or those taking interacting medications.
When Does Revefenacin Patent Expiration Occur?
Information regarding the specific patent expiration dates for revefenacin is available through resources like DrugPatentWatch.com [3]. Patents protect the intellectual property of a drug, and their expiration allows for the potential development of generic versions.
How Does Revefenacin Compare to Other Anticholinergics?
Revefenacin is part of a class of medications known as anticholinergics, which also includes tiotropium and aclidinium. These drugs work by blocking the action of acetylcholine in the airways, leading to bronchodilation. While they share a similar mechanism of action, differences in their pharmacokinetic profiles, such as bioavailability and half-life, can influence dosing regimens and potential drug interactions [4].
What are the Potential Side Effects of Revefenacin?
Common side effects associated with revefenacin use can include dry mouth, urinary tract infection, and constipation [2]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020467s000lbl.pdf
2. https://www.drugs.com/revefenacin.html
3. https://drugpatentwatch.com/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082614/